Abstract. It is sometimes difficult to diagnose Lynch syndrome by the simple but strict clinical criteria, or even by the definitive genetic testing for causative germline mutation of mismatch repair genes. Thus, some practical and efficient screening strategy to select highly possible Lynch syndrome patients is exceedingly desirable. We performed a comprehensive study to evaluate the methylation status of whole MLH1 promoter region by direct bisulfite sequencing of the entire MLH1 promoter regions on Lynch and non-Lynch colorectal cancers (CRCs). Then, we established a convenient assay to detect methylation in key CpG islands responsible for the silencing of MLH1 expression. We studied the methylation status of MLH1 as well as the CpG island methylator phenotype (CIMP) and immunohistochemical analysis of mismatch repair proteins on 16 cases of Lynch CRC and 19 cases of sporadic CRCs with high-frequency microsatellite instability (MSI-H). Sensitivity to detect Lynch syndrome by MLH1 (CCAAT) methylation was 88% and the specificity was 84%. Positive likelihood ratio (PLR) was 5.5 and negative likelihood ratio (NLR) was 0.15. Sensitivity by mutational analysis of BRAF was 100%, specificity was 84%, PLR was 6.3 and NLR was zero. By CIMP analysis; sensitivity was 88%, specificity was 79%, PLR was 4.2, and NLR was 0.16. BRAF mutation or MLH1 methylation analysis combined with MSI testing could be a good alternative to screen Lynch syndrome patients in a cost effective manner. Although the assay for CIMP status also showed acceptable sensitivity and specificity, it may not be practical because of its rather complicated assay.
Introduction
A subset of colorectal cancer (CRC), either hereditary or sporadic, is caused by deficient mismatch repair (MMR) machinery and exhibits distinct clinicopathological characteristics compared with the majority of sporadic CRCs. The hereditary type of MMR-deficient cancer is known as Lynch syndrome or hereditary non-polyposis colorectal cancer (HNPCC). However, accurate diagnosis of Lynch syndrome from sporadic CRC is sometimes difficult because of its less obvious clinicopathological characteristics compared with familial adenomatous polyposis (FAP), another type of hereditary CRC syndrome which has observable numbers of polyps in the colon and rectum. Also, germline mutation of cancer-causing MMR genes cannot always be detected in Lynch syndrome. Deficiency in MMR machinery, either by hereditary or sporadic reasons, causes instability (length alteration by slippage) of microsatellite sequences. High-level microsatellite instability (MSI-H), which is frequently observed in mononucleotide repeat markers such as BAT25, BAT26, BAT40 (1, 2) , is demonstrated in a majority of MMR-deficient cancers (3) (4) (5) (6) . Accordingly, the MSI test is an ideal strategy to select highly probable Lynch syndrome patients from sporadic CRC patients. The main difference between sporadic and hereditary CRC with MMR defect is understood as follows: germline inactivation of MMR genes (MLH1, MSH2, MSH6, and PMS2) underlies HNPCC whereas ONCOLOGY REPORTS 21: 1577 -1583 , 2009 Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability HITOSHI (11) . Recently, the CRCs with an MMR deficiency can simply be distinguished by a histopathological observation without IHC, because typical histopathological features of these tumors have been elucidated and been generally recognized. This will also help to diagnose Lynch syndrome.
CRCs with an MMR deficiency, including both hereditary and sporadic forms, can be diagnosed either by the MSI test or IHC study of MMR proteins. However, in order to diagnose Lynch syndrome, we need some additional approaches, such as a molecular method, to distinguish sporadic from hereditary forms of CRC with both having the MMR deficiency. In this study, we focused on the methylation patterns of the MLH1 promoter as well as BRAF mutational status and CpG island methylator phenotype (CIMP) status to assess these molecular markers to help in pre-selection of Lynch syndrome at a stage between the initial MSI test and the final germline mutational analysis.
Materials and methods
Tissue samples. Tumor tissues and samples of the corresponding normal mucosa were obtained from CRC patients who had undergone curative surgery at Okayama University and the Royal Brisbane Hospitals in Brisbane, Queensland. Ethical approval was obtained and we obtained informed consent in writing from all subjects. Tumor staging was based on Dukes classification. Samples of both tumor and normal mucosal tissue were stored at -80˚C and DNA was extracted by the standard procedure involving digestion with proteinase K and phenol-chloroform extraction.
Direct sequencing of nested MSP products from the MLH1
promoter. Bisulfite-treated genomic DNA samples were amplified with primers specific for the promoter region of the MLH1 gene. Primer sequences for the first PCR were: MLH1-F (5'-GGAGTGAAGGAGGTTAIGGGTAAGT-3') and MLH1-R (5'-ATTCACCACTATCTCITCCAACC-3'), and primer sequences for 'methylated' and 'unmethylated' for the nested PCR were: (a) M-F (5'-GTAGATGTTTTATTAG GGTCGC-3') and MLH1-R and (b) U-F (5'-GTAGATGTTT TATTAGGGTTGTGT-3') and MLH1-R, generating fragment lengths of 722 and 511 bp, respectively. Conditions of the first PCR and the nested PCR were as follows: 95˚C for 15 min; 45 cycles of 95˚C for 30 sec, 58˚C for 30 sec and 72˚C for 30 sec; and finally, 7 min at 72˚C. The nested PCR products were purified using a QIAquick PCR purification kit (Qiagen) and directly sequenced using a Thermo Sequenase sequencing kit (Amersham, Corp., Piscataway, NJ) and a SQ-5500E Hitachi Automated DNA sequencer.
Bisulfite modification and detection of methylation status of multiple loci. Sodium bisulfite modification was performed using a CpGenome DNA modification kit (Intergen Co., New York, NY). The methylation status of MINT1, MINT2, MINT31, CACNA1G, p16 INK4a , p14 ARF , COX2, DAPK, DCC
and MGMT was evaluated and determined by combined bisulfite restriction analysis (COBRA) using previously described procedures (12) (13) (14) (15) (16) (17) .
Methylation analysis for MLH1. The methylation status of MLH1 was determined by a newly established method which we described elsewhere (18) . The methylation of the CpG islands located upstream of the MLH1 promoter was not shown to cause silencing but rather was age related. However, methylation at a 3'-small region closer to the transcription start site invariably correlated with the absence of MLH1 expression in vitro and in colorectal tumors (19) . Accordingly, we needed to use the two sets of primers to evaluate the methylation status of both the upstream and downstream regions. Our method enabled us to distinguish MLH1-5' region sequences that were methylated or unmethylated by determining whether the fragments produced were 120 or 186 bp long. A similar approach was used for PCR analysis of the MLH1-3' region and the methylated and unmethylated 3' region (termed CCAAT region) sequences were distinguished by the presence of, 122 and 232 bp fragments, respectively.
Microsatellite analysis. The MSI testing for each tumor was determined on the basis of an examination of 5 microsatellite markers (BAT25, BAT26, D2S123, D5S346, D17S250) by our previously described method (20) . We classified tumors as MSI-H if two of the markers displayed MSI. Tumors displaying no MSI with any of the microsatellite markers that we tested were classified as MSS.
Detection of BRAF codon 600, KRAS codon 12 and 13
mutations. BRAF mutations at codon 600 and KRAS mutations at codons 12 and 13 were determined using standard protocols as we described previously (18) . We confirmed the nature of each of the mutations that we detected by our RFLP analysis by sequencing the appropriate DNA samples in a Hitachi Autosequencer SQ-5500E used in accordance with the manufacturer's instructions.
Immunohistochemical analysis for MLH1. Immunohistochemical (IHC) staining for MLH1 (Clone G168-728, 1 mg/ml; PharMingen, San Diego, CA), MSH2 (Clone FE11, 0.5 mg/ml; Oncogene Science, Cambridge, MA), MSH6 (Clone 44, 0.5 mg/ml; Transduction Laboratory, Lexington, KY), and PMS2 (Clone A16-4; PharMingen) were performed as described previously (21) . We used diamino-benzidine as a chromogen and hematoxylin as a nuclear counterstain. The only foci that were scored as negative were those for which there was definite evidence of positively staining admixed (or surrounding) non-neoplastic tissues such as normal colonic mucosal cells, lymphocytes or stromal cells. The normal staining pattern for MLH1, MSH2 and MSH6 was nuclear. Tumor cells that exhibited an absence of nuclear staining, in the presence of non-neoplastic cells with nuclear staining, were considered to have an abnormal pattern.
Statistical analysis. All statistical analysis was performed using JMP4.05J (SAS Institute, Inc., Cary, NC). Differences in frequencies were evaluated by the Fisher's exact test or Pearson's Chi-square test where appropriate. The association among the average number of methylated loci of 3 CRC subsets was analyzed using the Wilcoxon/Kruskal-Wallis test. All reported P-values are 2-sided and a P<0.05 was considered statistically significant. Confidence intervals for sensitivity and specificity were based on confidence intervals for the corresponding false negative and false positive error rates considered as independent binomial random variables, using tables appropriate for small samples (22) . The positive likelihood ratio (PLR) is equal to (1-ß)/· and the negative likelihood ratio (NLR) is equal to ß/(1-·), where · and ß are the false positive and false negative error rates, respectively. Confidence intervals for the positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were obtained by numerical approximation using a discretized likelihood; the nominal coverage of 95% was confirmed on all possible combinations of · and ß on the interval: 0< ·,ß <0.3.
Results

Direct sequencing of bisulfite-PCR products in the MLH1
promoter region Methylation allele-specific direct sequencing. We sequenced bisulfite-treated nested PCR products to obtain reliable information about the methylation status of the CpG islands that are known to be located in the nt 1031-1600 region of the MLH1 promoter. Fig. 1a shows the results that we obtained in a pilot direct sequencing study of 2 MSI-H CRCs and 2 CRCs with Lynch syndrome. The primers that we chose made it easy to distinguish between sequences containing methylated and unmethylated versions of the CpG doublets in the regions that we were targeting. Cytosine of the CpG islands in the promoter region of MLH1 remained as cytosine in the two sporadic MSI-H CRC tissues (01T and 07T), but converted to thymine in the two CRC tissues of Lynch syndrome patients (15T and 17T).
The methylation status of the two distinct MLH1 promoter regions in CRCs of Lynch syndrome and sporadic MSI-H CRCs.
We assessed the methylation status of both 5' region and 3' regions of the MLH1 promoter using a methylationspecific single PCR (MSSP) comparing CRCs of Lynch syndrome and sporadic MSI-H CRCs (Fig. 1b) . By this method we have already shown that methylation in the 3' region is highly correlated with the silencing of the MLH1; ie, loss of expression of MLH1 (18) . In this study, methylation of the 5' region of the MLH1 promoter was observed in 18 out of 19 sporadic MSI-H (Figs. 1b and 2 ), while methylation of the 3' region was observed in 16 out of 19 sporadic MSI-H. In contrast, few cases of methylation were observed in CRCs of Lynch syndrome patients: methylation of the 3' region was only detected in 2 out of 16 tumors (T6 and T20), while 5' methylation was observed in 3 out of 16 tumor samples (T6, T7 and T20) (Figs. 1b and 2 ). Fig. 2 . The majority of the sporadic MSI-H CRCs lost the expression of MLH1. However, in Lynch syndrome CRCs only 7 out of 16 samples showed loss of expression of MLH1, and germline mutation of MLH1 was confirmed in 2 of them. Two samples showed methylation in the 3' region of MLH1. Five samples showed loss of expression of MSH2 and among them two samples were confirmed as germline mutations of MSH2. Two samples showed loss of expression of MSH6 with one germline mutation confirmed and two samples showed loss of expression of PMS2 without detection of germline mutations. One Lynch syndrome sample showed loss of expression of both MLH1 and PMS2. Fig. 3 shows the methylation status of CIMP markers, including MINT1, MINT2, MINT31, p16 INK4a and CACNA1G, in sporadic MSI-H CRCs and Lynch syndrome CRCs. We also assessed the methylation status of non-CIMP genes, including p14 ARF , DAPK, COX2, MGMT and DCC, for comparison. We define CIMP (+) as >3 markers showing methylation among the CIMP 5 markers. Fifteen out of 19 sporadic MSI-H cancers were determined to be CIMP (+), whereas there were no 
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CIMP (+) results in Lynch syndrome CRCs. Among the non-CIMP markers, p14
ARF showed a similar methylation pattern to the CIMP panel and showed methylation mainly in sporadic MSI-H CRCs. Almost no methylation was observed in either DAPK or COX2 in Lynch syndrome, whereas infrequently methylation of both promoters was observed in sporadic MSI-H. In contrast, DCC was frequently methylated throughout the sporadic MSI-H and Lynch syndrome CRCs, whereas MGMT showed methylation less frequently overall but at similar levels in both types of CRCs.
Efficiency of molecular screening for Lynch syndrome from MSI-H colorectal cancer patients.
As MSI-H tumors are characterized by MMR deficiency and include both Lynch syndrome and sporadic CRC, efficient elimination of sporadic CRC from total MSI-H CRC improves efficiency in diagnosing Lynch syndrome (Table I) . Promoter methylation of the 3' region of MLH1 (CCAAT methylation) was identified in 16 out of 19 sporadic MSI-H CRCs and 2 out of 16 Lynch syndrome cases. Thus if CCAAT non-methylation is considered a positive result for diagnosing Lynch syndrome, this corresponds to a sensitivity of 88% and specificity of 84%. Positive likelihood ratio (PLR) of non-CCAAT methylation among MSI-H CRC in predicting Lynch syndrome was 5.5 and negative likelihood ratio (NLR) of CCAAT methylation in predicting Lynch syndrome was 0.15. When the mutational status of BRAF instead of the CCAAT methylation is considered, sensitivity for the diagnosis of Lynch syndrome is 100% and the specificity is 84%. Thus, PLR of BRAF mutation among MSI-H CRCs to diagnose sporadic MSI-H CRCs was 6.3 and NLR of wild-type of BRAF to diagnose Lynch syndrome was zero. We also evaluate CIMP status using 5 markers as >3 markers being considered as positive for CIMP. Sensitivity for CIMP negative plus MSI-H to diagnosis Lynch syndrome was 88% and the specificity was 79%. PLR of CIMP negative for Lynch syndrome was 4.2 and NLR of CIMP positive for Lynch syndrome CRC was 0.16.
Discussion
Lynch syndrome is a dominantly inherited syndrome characterized by the development of CRC, endometrial cancer and other cancers and the presence of MSI in tumors. The Bethesda guidelines have been proposed to recruit families suspected of Lynch syndrome that require further molecular analysis (seeking germline mutation of MMR genes). In this study we evaluated how methylation status of MLH1, CIMP promoters and mutational status of BRAF V600E would help to improve selection of suspected Lynch syndrome patients before germline analysis.
The Bethesda guideline and revised Bethesda guideline are selection criteria designed to improve the probability of finding of Lynch syndrome cases by applying the MSI test. The recommended reference panel, referred to as the Bethesda panel, was proposed and broadly used to elucidate the tumors caused by MMR deficiency (23) . In other words, the Bethesda guideline aims to eliminate sporadic CRC with MMR deficiency by using pattern recognition of the phenotypic cancer features expressed in a family before applying the MSI test. Another option to eliminate sporadic CRC with MMR deficiency is to use molecular tests that define the alterations 'typically' (more preferably 'specifically') observed in either hereditary or sporadic CRC with MMR defects after selection by the MSI test.
Promoter hypermethylation of the MLH1 gene is considered to be associated with absence of expression of the MLH1 protein and causes sporadic CRCs with MSI-H (8, (24) (25) (26) . However, difficulty in promoter analysis of MLH1 has been demonstrated in many studies because the methylation pattern in the MLH1 promoter is unique. MLH1 has few CpG islands in its promoter, especially on the 3' side, and most of the methylation dense area, located upstream of the promoter, has been shown to have no relation to the silencing of MLH1 (19) . Conversely, methylation at a small 3' region closer to the transcription start site invariably correlates with the absence of MLH1 expression in colorectal cell lines and surgically removed materials (27) . Deng et al identified a CCAAT box in this region, which specifically bound transcription factor CBF (28) . Methylation of a CpG island located two base pairs upstream of the CCAAT box inhibits the binding of CBF to the CCAAT box. We have shown that this unique methylation is well correlated with the silencing of MLH1 using our unique methylation-specific PCR after confirming the methylation pattern by bisulfite sequencing throughout the promoter. In this study, we assessed the usefulness of this methylation (termed CCAAT methylation) to recruit Lynch syndrome cases in comparison with the mutation status of BRAF V600E or the CIMP status of the tumor.
Sensitivity and specificity to diagnose Lynch syndrome by a combination of MSI-H and either CCAAT methylation or BRAF mutation were similar, as the sensitivities were 88 and 100% and the specificity of both was 84%.
Probability P of having a disease is related to odds O of having the disease by the simple equation 0 = P/1-P. If the fraction of MSI-H cases that are Lynch syndrome is estimated to be ~X% then the probability that a case is Lynch syndrome based only on its being MSI-H is X/100 and the odds of being Lynch syndrome are: X/100-X. Thus, a person with a probability of having Lynch syndrome of X% before the CCAAT methylation test has odds of X/100-X of having Lynch syndrome. After a positive test result for CCAAT methylation, the odds change to 5.5X/100-X. Because, 0 = P/1-P ⇒ P = 0/0+1, the probability after the test result is P = 5.5X/4.5X+100.
CCAAT methylation at MLH1 was identified as being specific to the sporadic MSI-H CRCs with the exception of 3 cases. All three cases lacked the mutation of BRAF and did not belong to the CIMP phenotype. Two of them lacked the IHC staining of MLH1. Although they did not meet the Amsterdam Criteria, some of them may belong to Lynch syndrome cases whose family history was not sufficient to meet the clinical criteria, even though there was elderly onset of cancer. On the other hand CCAAT methylation was identified in 2 cases of Lynch syndrome and neither case showed a confirmed germline mutation of the MLH1 gene. Whether silencing of MLH1 is caused by methylation of both alleles or by hemi-methylation (second hit) plus an unidentified germline mutation (first hit) of MLH1 is unknown. Both of the cases were wild-type in both KRAS and BRAF and did not show CIMP. Of course CIMP can be applied as an additional marker to select Lynch syndrome among the MSI-H CRCs, although the method to assess CIMP is more complicated than the single methylation assay of MLH1 CCAAT. In addition, sensitivity and specificity of CIMP to diagnose Lynch syndrome were not superior to either BRAF mutation or MLH1 methylation.
In this study, primary selection of MMR deficient CRCs was not done by IHC study of the MMR proteins. Thus, we cannot assess how IHC staining improves the diagnosis of Lynch syndrome. Also, the current MSI test has several problems, as false positive and false negative cases based on results of the NCI panel have been identified. For example, Lynch syndrome caused by the germline mutation of MLH6 infrequently shows MSI-H by the Bethesda panel markers. By using multiple mononucleotide markers, MLH6 mutants can be properly diagnosed as MSI-H. In this study series, MSI-H Table I . Sensitivity and specificity of Lynch syndrome screening with MLH1 CCAAT methylation and BRAF V600E mutation among colorectal cancer with MSH-H. ---------------------------------------------------------------------------------------------------- PLR, positive likelihood ratio; NLR, negative likelihood ration; LCI, lower confidence intervals; UCI, upper confidence intervals; CCAAT meth, MLH1 promoter methylation at CCAAT box; BRAF wt, wild-type for BRAF; BRAF mt, mutation for BRAF and CIMP, CpG island methylator phenotype.
-----------------------------------------------------------------------------------------------------Lynch Sporadic Sensitivity (LCL-UCL) Specificity (LCL-UCL) PLR (LCL-UCL) NLR (LCL-UCL) -----------------------------------------------------------------------------------------------------
-- --------------------------------------------------------------------------------------------------- status was assessed by the classical Bethesda panel, so that several tumors with MMR defects including those with MSH6 defects could have been missed. Accordingly, if a more precise MSI test to define CRC with MMR can be achieved, MSI plus a molecular test including BRAF mutation and CCAAT methylation of MLH1 could be a good strategy to narrow down the possible Lynch syndrome candidates, or could even substitute for the final test, since the ultimate examination of germline mutation of MMR genes does not always show mutation in Lynch syndrome patients. BRAF V600E could be the most cost effective and efficient pre-selection molecular strategy targeting CRCs with MSI-H.
